Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. by Katie D. Pool (20141584)

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

FASN modulation in the presence of serum. by Camilla Albano (16446679)

CCND1 is a target gene of miR-1247-3p. by Dequan Wang (6007007)

FASN modulation impacts HSV-1 replication and infectivity. by Camilla Albano (16446679)

HSV-1 infection modulates the fatty acid synthase. by Camilla Albano (16446679)

A frame from the video with behaviors annotated in a custom way. by Piotr Popik (292215)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Depletion of <i>cyd-1</i> leads to decreased oocyte quality and increased apoptosis without affecting the DNA damage response (DDR). by Umanshi Rautela (20235283)

Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg by Kristin R. Anderson (5478734)

Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf by Kristin R. Anderson (5478734)

Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients. by Michele Angelo Colombo (22446342)

“…This decrease was larger in the disconnected than in the contralateral cortex. …”

Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”

Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”

Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”

Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf by Kai Sun (140584)

“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”

Data Sheet 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx by Kai Sun (140584)

“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”